Latest news with #Antech
Business Insider
18-06-2025
- Health
- Business Insider
How your pet's next vet visit could help protect your health, too
We tend to think of veterinarians as the people who treat our pets' aches and illnesses. Behind those exam room doors; however, there's a bigger story unfolding that connects your pet's health to your own. In celebration of Veterinary Appreciation Day, we're spotlighting the extraordinary impact of veterinary professionals beyond the exam room. We spoke with Dr. Molly McAllister, global chief medical officer at Mars Veterinary Health, to talk about how everyday veterinary visits are helping spot public health risks early, protect communities, and shape the future of medicine. Q: Most people think of veterinarians as animal doctors. When did you realize veterinary medicine had far broader implications beyond just pet health? Like most veterinarians, my journey started with a lifelong love of animals. Veterinary school is where I began to see the scale of health information flowing through clinics. As I went on to obtain a Master's degree in public health, the overlap of human health and animal health became central to my studies. At Mars Veterinary Health, nearly 70,000 pet-loving veterinary professionals touch the lives of millions of pets and their owners around the world each year. This gives us access to deep knowledge and insights that can drive meaningful global impact. Veterinary care isn't solely about animals; it comes with a responsibility to public health, too. That's why we prioritize the concept of One Health: The inextricable link between people, animals, and the environment. Q: Why are pets such powerful early indicators of public health trends? Companion animals share more than a loving relationship with us, they also breathe the same air, walk on the same sidewalks, and are exposed to many of the same health risks. In fact, they're often the first to show signs of emerging public health issues. For example, a collaborative study by VCA Animal Hospitals and Antech that examined over 1,000 pets living with people who had COVID-19 showed the interconnection between human and animal health. Our researchers found that 33% of dogs and 27% of cats tested positive for SARS-CoV-2 antibodies. While this is not the same as developing disease, this result demonstrates how pet health monitoring can reveal important risks to human health. Real-world links like these demonstrate the veterinary profession's critical role in maintaining and promoting One Health. Our recent Mars Veterinary Health Science Impact Report shows the value of veterinary data in identifying public health risks. It brings together research from our global veterinary care network and offers insights from millions of pets. From this, we can spot trends sooner to keep improving global health at scale. Q: What kinds of research is Mars Veterinary Health contributing to right now? As a family-owned, purpose-led company, we've long encouraged and invested in veterinary science and clinical research across our global network. This allows us to enhance the quality of care we deliver and help advance veterinary medicine industry-wide. With millions of pets coming through our doors, we feel a responsibility and opportunity to use our knowledge and insights for greater good. Clinician scientists across Mars Veterinary Health are continually conducting and publishing leading clinical research — many the first and largest studies of their kind. Last year alone, this amounted to more than 450 peer-reviewed publications from our Associates worldwide. Across 140+ of our clinics in the US and Europe, we're also running clinical studies that will help shape the future of veterinary care. Our Mars Veterinary Health teams also enable the Mars Petcare Biobank, one of the largest, most comprehensive real-world pet health studies that aims to follow 20,000 dogs and cats over a decade to detect potential early signs of disease and identify new ways to prevent and predict illness. This study has the potential to transform pet health for generations to come, and pet owners across the US are invited to sign up here. Q: Where do pet owners fit into all of this? How can they make a difference? Every pet healthcare decision starts with trust between a pet owner and their veterinarian, a partnership that should grow through every stage of a pet's life. This recently played out at some of our Linnaeus clinics promoting responsible antibiotic usage. We shared a video in 20+ languages to help pet owners better understand antimicrobial resistance and responsible antibiotic use. Our veterinary teams noticed more thoughtful conversations and fewer requests for unnecessary prescriptions as a result. This is just one example of the important partnership between veterinary teams and pet owners to protect the health of pets, people, and the planet. Q: What's preventing deeper understanding of veterinary medicine's role in public health? Awareness is growing, but we still have work to do. Veterinarians deeply understand the human-animal bond and their role in safeguarding it and therefore have always played a role in public health, from food safety to spotting disease trends and supporting community wellbeing. The opportunity now is to strengthen the public's understanding of how pet healthcare contributes to public health. Greater awareness has the potential to strengthen our ability to drive lasting, positive change. Q: What's your vision for the future of the veterinary profession? My 8-year-old daughter wants to be a veterinarian. Thinking of her future and others like her keeps me focused on building a profession that inspires and cares for the next generation. For me, the goal is better care for pets everywhere, powered by a connected, global veterinary community. That means supporting the people behind the care through training, education, and research. As a leading post-graduate education provider, I'm proud that Mars Veterinary Health helps grow the next generation of clinician-scientists — giving them the tools to shape what's next. Q: If there's one takeaway you want readers to leave with, what is it? I want people to see their veterinarians as more than someone who treats a cough or a limp. They're partners in your pet's care at every stage and a key health professional in their network. Veterinary teams are knowledgeable, pet-obsessed allies who aim to do what's best for your pet and you. In doing so, they're helping protect public health in your community. The next major medical breakthrough might not come from a research lab but from your local veterinary clinic.
Yahoo
12-05-2025
- Health
- Yahoo
Antech™ Expands Vector-Borne Disease Portfolio with Enhanced Accuplex™ and Most Comprehensive PCR Panel to Date
Tens of Millions of Dogs Remain Untested for Exposure to the Most Common Vector-Borne Diseases Despite Rising Disease Prevalence LOVELAND, Colo., May 12, 2025--(BUSINESS WIRE)--Antech™, a global veterinary diagnostics, technology and imaging company, today announced the launch of two new vector-borne disease diagnostics in their expanding portfolio: enhanced Accuplex™, a reference lab canine vector-borne disease (CVBD) screening test which now detects seven pathogens, and an enhanced vector-borne disease PCR profile, the veterinary industry's most comprehensive PCR panel of its kind. Based on current testing data disseminated by the Companion Animal Parasite Council (CAPC), Antech scientists estimate that tens of millions of dogs in North America are not tested for exposure to CVBDs annually. As cases of canine heartworm disease and tick-borne pathogens continue to rise in both endemic and emerging regions, Antech is committed to expanded care for dogs being exposed to these serious diseases. Enhanced Accuplex can now detect antibodies to three Ehrlichia species, and two Anaplasma species, alongside heartworm (Dirofilaria immitis) antigen, and antibodies to confirm exposure to Lyme borreliosis (Borrelia burgdorferi). With the rising prevalence of tick-borne diseases across North America, this expanded detection capability ensures broader coverage and greater confidence in diagnostic results, ultimately supporting informed clinical decision-making. Antech is also offering a new enhanced vector-borne disease PCR panel for dogs and cats to ensure veterinarians have comprehensive diagnostic offerings to meet emerging disease risks. While the traditional "big four" vector-borne diseases (heartworm, Lyme borreliosis, anaplasmosis, and ehrlichiosis) remain the most diagnosed in North America, rising cases and increased geographical spread of Rocky Mountain spotted fever, babesiosis, cytauxzoonosis, and others demand wider flexibility in testing. Antech's enhanced vector-borne disease PCR panel is unique in the industry in providing veterinarians with the most comprehensive array of vector-borne pathogens in the veterinary industry to date. The launch of enhanced Accuplex and the comprehensive vector-borne disease PCR panel follows the March 2025 announcement of Antech's new patient-side vector-borne disease screening test, trūRapid™ FOUR, a lateral flow test using whole blood, serum, or plasma to detect heartworm antigen and the complete suite of tick-borne antibodies encompassed in the enhanced Accuplex reference lab offering. Jimmy Barr, DVM, DACVECC, Chief Medical Officer for Mars Petcare's Science & Diagnostics division and Antech, said: "Today, we celebrate our capability to offer veterinarians the flexibility to screen for these life-threatening vector-borne diseases with a complete portfolio of reference lab and in-house diagnostic offerings, meaning no other lab matches Antech in the breadth and depth of parasite and vector-borne diseases screening. The addition of two new Ehrlichia markers and one new Anaplasma marker to our Accuplex reference lab platform, as well as the launch of our PCR panel, will help ensure we can test more comprehensively for exposure to the most common vector-borne pathogens in North America." For more information, please visit Notes to editors Key Features of enhanced Accuplex include: Expanded Pathogen Detection: Accuplex now detects three Ehrlichia species and two Anaplasma species, increasing test sensitivity and allowing broader vector-borne disease screening across more regions. Reference Lab Testing: Ensures reproducibility and reduces variability with highly trained technicians performing each assay. Peace of Mind: Provides reliable and precise testing, fostering confidence among veterinarians and pet owners alike. Key Features of enhanced Vector-Borne Disease PCR include: Broader pathogen detection: This panel detects more vector-borne pathogens giving clinicians the best opportunity to identify the underlying cause of illness. PCR vs. serology: While antibody production can lag behind infection, PCR is often the better choice for when VBD is suspected but not confirmed. It's also highly valuable when serology may miss early infection. Common yet overlapping clinical signs: Vector-borne diseases frequently present with nonspecific or overlapping signs; improved PCR helps clarify these complex cases. Resistance marker: The panel includes a new resistance marker, specifically detecting atovaquone resistance - a growing concern in the treatment of Babesia and Cytauxzoon infections. This supports responsible antimicrobial use and better-informed treatment decisions. Antech at AVMA Visit Antech at the AVMA Convention 2025 and the 40th World Veterinary Association Congress which will take place July 18-22, 2025 in Washington, D.C. to find out more about our vector-borne disease portfolio and to speak to a sales representative. About Antech Antech is a global veterinary diagnostics company, driven by our passion for innovation that helps veterinarians deliver better animal health outcomes. Our products and services span 90+ reference laboratories around the globe; in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; veterinary imaging and technology; veterinary professional education and training; and board-certified specialist support services. View source version on Contacts Media inquiries: Sarah Doyle, Antech: Mia Nolan, Kekst CNC:
National Post
12-05-2025
- Health
- National Post
Antech™ Expands Vector-Borne Disease Portfolio with Enhanced Accuplex™ and Most Comprehensive PCR Panel to Date
Article content Article content LOVELAND, Colo. — Antech™, a global veterinary diagnostics, technology and imaging company, today announced the launch of two new vector-borne disease diagnostics in their expanding portfolio: enhanced Accuplex™, a reference lab canine vector-borne disease (CVBD) screening test which now detects seven pathogens, and an enhanced vector-borne disease PCR profile, the veterinary industry's most comprehensive PCR panel of its kind. Article content Based on current testing data disseminated by the Companion Animal Parasite Council (CAPC), Antech scientists estimate that tens of millions of dogs in North America are not tested for exposure to CVBDs annually. As cases of canine heartworm disease and tick-borne pathogens continue to rise in both endemic and emerging regions, Antech is committed to expanded care for dogs being exposed to these serious diseases. Article content Enhanced Accuplex can now detect antibodies to three Ehrlichia species, and two Anaplasma species, alongside heartworm (Dirofilaria immitis) antigen, and antibodies to confirm exposure to Lyme borreliosis (Borrelia burgdorferi). With the rising prevalence of tick-borne diseases across North America, this expanded detection capability ensures broader coverage and greater confidence in diagnostic results, ultimately supporting informed clinical decision-making. Article content Antech is also offering a new enhanced vector-borne disease PCR panel for dogs and cats to ensure veterinarians have comprehensive diagnostic offerings to meet emerging disease risks. While the traditional 'big four' vector-borne diseases (heartworm, Lyme borreliosis, anaplasmosis, and ehrlichiosis) remain the most diagnosed in North America, rising cases and increased geographical spread of Rocky Mountain spotted fever, babesiosis, cytauxzoonosis, and others demand wider flexibility in testing. Antech's enhanced vector-borne disease PCR panel is unique in the industry in providing veterinarians with the most comprehensive array of vector-borne pathogens in the veterinary industry to date. Article content The launch of enhanced Accuplex and the comprehensive vector-borne disease PCR panel follows the March 2025 announcement of Antech's new patient-side vector-borne disease screening test, trūRapid™ FOUR, a lateral flow test using whole blood, serum, or plasma to detect heartworm antigen and the complete suite of tick-borne antibodies encompassed in the enhanced Accuplex reference lab offering. Article content Jimmy Barr, DVM, DACVECC, Chief Medical Officer for Mars Petcare's Science & Diagnostics division and Antech, said: 'Today, we celebrate our capability to offer veterinarians the flexibility to screen for these life-threatening vector-borne diseases with a complete portfolio of reference lab and in-house diagnostic offerings, meaning no other lab matches Antech in the breadth and depth of parasite and vector-borne diseases screening. The addition of two new Ehrlichia markers and one new Anaplasma marker to our Accuplex reference lab platform, as well as the launch of our PCR panel, will help ensure we can test more comprehensively for exposure to the most common vector-borne pathogens in North America.' Article content Key Features of enhanced Accuplex include: Article content Expanded Pathogen Detection: Accuplex now detects three Ehrlichia species and two Anaplasma species, increasing test sensitivity and allowing broader vector-borne disease screening across more regions. Reference Lab Testing: Ensures reproducibility and reduces variability with highly trained technicians performing each assay. Peace of Mind: Provides reliable and precise testing, fostering confidence among veterinarians and pet owners alike. Article content Broader pathogen detection: This panel detects more vector-borne pathogens giving clinicians the best opportunity to identify the underlying cause of illness. PCR vs. serology: While antibody production can lag behind infection, PCR is often the better choice for when VBD is suspected but not confirmed. It's also highly valuable when serology may miss early infection. Common yet overlapping clinical signs: Vector-borne diseases frequently present with nonspecific or overlapping signs; improved PCR helps clarify these complex cases. Resistance marker: The panel includes a new resistance marker, specifically detecting atovaquone resistance – a growing concern in the treatment of Babesia and Cytauxzoon infections. This supports responsible antimicrobial use and better-informed treatment decisions. Article content Antech at AVMA Article content Visit Antech at the AVMA Convention 2025 and the 40th World Veterinary Association Congress which will take place July 18-22, 2025 in Washington, D.C. to find out more about our vector-borne disease portfolio and to speak to a sales representative. Article content Antech is a global veterinary diagnostics company, driven by our passion for innovation that helps veterinarians deliver better animal health outcomes. Our products and services span 90+ reference laboratories around the globe; in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; veterinary imaging and technology; veterinary professional education and training; and board-certified specialist support services. Article content Article content Article content Article content Article content
Business Wire
12-05-2025
- Health
- Business Wire
Antech™ Expands Vector-Borne Disease Portfolio with Enhanced Accuplex™ and Most Comprehensive PCR Panel to Date
LOVELAND, Colo.--(BUSINESS WIRE)--Antech™, a global veterinary diagnostics, technology and imaging company, today announced the launch of two new vector-borne disease diagnostics in their expanding portfolio: enhanced Accuplex™, a reference lab canine vector-borne disease (CVBD) screening test which now detects seven pathogens, and an enhanced vector-borne disease PCR profile, the veterinary industry's most comprehensive PCR panel of its kind. Based on current testing data disseminated by the Companion Animal Parasite Council (CAPC), Antech scientists estimate that tens of millions of dogs in North America are not tested for exposure to CVBDs annually. As cases of canine heartworm disease and tick-borne pathogens continue to rise in both endemic and emerging regions, Antech is committed to expanded care for dogs being exposed to these serious diseases. Enhanced Accuplex can now detect antibodies to three Ehrlichia species, and two Anaplasma species, alongside heartworm (Dirofilaria immitis) antigen, and antibodies to confirm exposure to Lyme borreliosis (Borrelia burgdorferi). With the rising prevalence of tick-borne diseases across North America, this expanded detection capability ensures broader coverage and greater confidence in diagnostic results, ultimately supporting informed clinical decision-making. Antech is also offering a new enhanced vector-borne disease PCR panel for dogs and cats to ensure veterinarians have comprehensive diagnostic offerings to meet emerging disease risks. While the traditional 'big four' vector-borne diseases (heartworm, Lyme borreliosis, anaplasmosis, and ehrlichiosis) remain the most diagnosed in North America, rising cases and increased geographical spread of Rocky Mountain spotted fever, babesiosis, cytauxzoonosis, and others demand wider flexibility in testing. Antech's enhanced vector-borne disease PCR panel is unique in the industry in providing veterinarians with the most comprehensive array of vector-borne pathogens in the veterinary industry to date. The launch of enhanced Accuplex and the comprehensive vector-borne disease PCR panel follows the March 2025 announcement of Antech's new patient-side vector-borne disease screening test, trūRapid™ FOUR, a lateral flow test using whole blood, serum, or plasma to detect heartworm antigen and the complete suite of tick-borne antibodies encompassed in the enhanced Accuplex reference lab offering. Jimmy Barr, DVM, DACVECC, Chief Medical Officer for Mars Petcare's Science & Diagnostics division and Antech, said: 'Today, we celebrate our capability to offer veterinarians the flexibility to screen for these life-threatening vector-borne diseases with a complete portfolio of reference lab and in-house diagnostic offerings, meaning no other lab matches Antech in the breadth and depth of parasite and vector-borne diseases screening. The addition of two new Ehrlichia markers and one new Anaplasma marker to our Accuplex reference lab platform, as well as the launch of our PCR panel, will help ensure we can test more comprehensively for exposure to the most common vector-borne pathogens in North America.' For more information, please visit Notes to editors Key Features of enhanced Accuplex include: Expanded Pathogen Detection: Accuplex now detects three Ehrlichia species and two Anaplasma species, increasing test sensitivity and allowing broader vector-borne disease screening across more regions. Reference Lab Testing: Ensures reproducibility and reduces variability with highly trained technicians performing each assay. Peace of Mind: Provides reliable and precise testing, fostering confidence among veterinarians and pet owners alike. Key Features of enhanced Vector-Borne Disease PCR include: Broader pathogen detection: This panel detects more vector-borne pathogens giving clinicians the best opportunity to identify the underlying cause of illness. PCR vs. serology: While antibody production can lag behind infection, PCR is often the better choice for when VBD is suspected but not confirmed. It's also highly valuable when serology may miss early infection. Common yet overlapping clinical signs: Vector-borne diseases frequently present with nonspecific or overlapping signs; improved PCR helps clarify these complex cases. Resistance marker: The panel includes a new resistance marker, specifically detecting atovaquone resistance - a growing concern in the treatment of Babesia and Cytauxzoon infections. This supports responsible antimicrobial use and better-informed treatment decisions. Antech at AVMA Visit Antech at the AVMA Convention 2025 and the 40th World Veterinary Association Congress which will take place July 18-22, 2025 in Washington, D.C. to find out more about our vector-borne disease portfolio and to speak to a sales representative. About Antech Antech is a global veterinary diagnostics company, driven by our passion for innovation that helps veterinarians deliver better animal health outcomes. Our products and services span 90+ reference laboratories around the globe; in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; veterinary imaging and technology; veterinary professional education and training; and board-certified specialist support services.
Associated Press
10-03-2025
- Health
- Associated Press
Antech Launches trūRapid™ FOUR: Simplifying Canine Vector-Borne Disease Screening for Veterinarians
Antech, a global veterinary diagnostics, technology and imaging company, today announced the launch of trūRapid™ FOUR, a comprehensive in-house canine vector-borne disease (CVBD) screening test. trūRapid™ FOUR is a lateral flow test used to detect canine antibodies to Anaplasma spp., Ehrlichia spp., and Lyme C6 ( Borrelia burgdorferi), as well as heartworm ( Dirofilaria immitis) antigen, using whole blood, serum, or plasma. Jimmy Barr, DVM, DACVECC, Chief Medical Officer for Mars Petcare's Science & Diagnostics division and Antech, said: 'With its speed, proven reliability, and streamlined workflow, trūRapid™ FOUR offers busy veterinary professionals a simple alternative to current testing protocols and, importantly, provides an affordable choice without compromising quality.' Key Features of trūRapid™ FOUR include: Streamlined Workflow: Requires just a few drops of sample, minimizing the need for additional blood draws or sample centrifugation. Eliminates manual snapping; the test reaction begins automatically when the sample and buffer is directly added. Proven Reliability: Excellent sensitivity and specificity when compared to reference laboratory testing. For Lyme, C6 ensures high specificity, preventing false positives caused by vaccination. Broad reactivity: E. canis, E. chaffeensis, and E. ewingii; A. phagocytophilum and A. platys. No refrigeration: Tests can be stored at room temperature for their entire shelf life, saving refrigerator space, simplifying inventory management, and eliminating the need to warm up the test before use. Eco-Friendly Design: Generates less plastic waste with no need for additional sample handling tubes — just the cartridge and a plastic pipette. About Antech Antech is a global veterinary diagnostics company, driven by our passion for innovation that helps veterinarians deliver better animal health outcomes. Our products and services span 90+ reference laboratories around the globe; in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; veterinary imaging and technology; veterinary professional education and training; and board-certified specialist support services. SOURCE: Antech Copyright Business Wire 2025. PUB: 03/10/2025 08:46 AM/DISC: 03/10/2025 08:47 AM
